Abstract
Parkinson’s disease is a syndrome that frequently includes drooling, i.e., the involuntary spillage of saliva over the lip margin. Such drooling places a severe burden on both the health and the quality of life of Parkinsonian patients. Its origin lies in the impairment of oral motor control and swallowing associated with Parkinson’s disease. It can be treated surgically or conservatively by reducing the production of saliva in the salivary glands, to which the parotid and submandibular glands make the greatest contribution. Botulinum neurotoxins A and B, administered to these glands, are in increasing use as treatment for drooling from various causes including Parkinson’s disease. Wide knowledge was gathered about preferred drugs, dosages, injection sites and injection-guiding techniques, albeit without providing evidence-based guidance or a clear rationale for the mode of action of the medication or any information about further influential or predictive factors for safety and efficacy. However, it is essential that the relevant glands be targeted accurately; although this can be done by using anatomical landmarks, the use of sonographic guidance seems preferable. In the hands of a trained injector, sonography is a quick and non-invasive imaging technique.
Similar content being viewed by others
References
Anagnostou E, Rentzos M, Alexakis T, Zouvelou V, Zambelis T, Evdokimidis I (2013) Volume matters: the influence of different Botulinum toxin A dilutions for sialorrhea in amyotrophic lateral sclerosis. Muscle Nerve 47:276–278
Arbouw ME, Movig KL, Koopmann M, Poels PJ, Guchelaar HJ, Egberts TC, Neef C, van Vugt JP (2010) Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 74:1203–1207
Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O’Connell D, Senard JM, Rascol O, Montastruc JL (1999) A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 22:213–215
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, PRIAMO study group (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649
Bateson M, Gibberd FB, Wilson RSE (1973) Saliva symptoms in Parkinson disease. Arch Neurol 29:274–275
Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L (2012) Safety and efficacy of Botulinum toxin type B for Treatment of sialorrhea in Parkinson’s disease: a prospective double-blind trial. Mov Disord 27:219–226
Chou KL, Evatt M, Hinson V, Kompoliti K (2007) Sialorrhea in Parkinson’s disease: a review. Mov Disord 16:2306–2313
DAHNO, Deutsche Gesellschaft für Hals-, Nasen-, Ohhrenheilkunde, Kopf- und Halschirurgie: Hypersalivation (2013) AWMF-Register Nr. 017/075, January 2013. http://www.awmf.org/uploads/tx_szleitlinien/017-075l_S2k_Hypersalivation_2013-02.pdf. Accessed Mar 2015
Damian A, Adlerb CH, Hentz JG, Shill HA, Caviness JN, Sabbagh MN, Evidente VG, Beach TG, Driver-Dunckley E (2012) Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson’s disease. Parkinsonism Relat Disord 18:1089–1093
Dogu O, Apaydin D, Sevim S, Talas DU, Aral M (2004) Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin A for the treatment of sialorrhea in patients with Parkinson’s disease. Clin Neurol Neurosurg 106:93–96
Eadie MJ, Tyrer JH (1965) Alimentary disorder in parkinsonism. Australas Ann Med 14:13–22
Egevad G, Petkova VY, Vilholm OJ (2014) Sialorrhea in patients with Parkinson’s disease: safety and administration of Botulinum neurotoxin. J Parkinson’s Dis 4:321–326
Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multi system atrophy. Mov Disord 16:1176–1177
Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, Siciliani L, Sabatelli M, Bentivoglio R (2011) Botulinum toxin A versus B in sialorrhea: a prospective, randomized, doubleblind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord 26:313–319
Hong JS, Sathe GG, Niyonkuru C, Munin MC (2012) Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve 46:535–539
Howlett DC (2003) High resolution ultrasound assessment of the parotid gland. Brit J Radiol 76:271–277
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Jost WH (1997) Gastrointestinal motility problems in patients with Parkinson’s disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 10:249–258
Jost WH (1999) Treatment of drooling in Parkinson’s disease with botulinum toxin. Mov Disord 14:1057
Kamble RC, Joshi AN, Mestry PJ (2013) Ultrasound characterization of salivary lesions. Int J Otorhinolaryngol Clin 5:77–90
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006) Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 21:704–707
Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G (2003) A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61:1279–1281
Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C (2003) Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685–688
Martignoni E, Pacchetti C, Godi L, Micieli G, Nappi G (1995) Automomic disorders in Parkinson’s diesase. J Neural Transm Suppl 45:11–19
Molloy L (2007) Treatment of sialorrhoea in patients with Parkinson’s disease: best current evidence. Curr Opinion Neurol 20:493–498
Montgomery J, McCusker S, Hendry J, Lumley E, Kubba H (2014) Botulinum toxin A for children with salivary control problems. Int J Pediatr Otorhinolaryngol 78:1970–1973
Nicaretta DH, de Rosso ALZ, Maliska C, Costa MMB (2008) Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson’s disease. Parkinsonism Relat Disord 14:338–341
Oppenheim H (1902) Kleine Beiträge zur Neuropathologie. J Psychol Neurol 1:129–146
Parkinson J (1817) An essay on the shaking palsy. Sherwood, Neely, and Jones, London
Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson’s disease. Lancel Neurol 2:107–116
Proulx M, de Courval FP, Wiseman MA, Panisset M (2005) Salivary production in Parkinson’s disease. Mov Disord 20:204–207
Schramm A, Bäumer T, Fietzek U, Heitmann S, Walter U, Jost WH (2014) Relevance of sonography for Botulinum toxin treatment of cervical dystonia: an expert statement. J Neural Transmission. PMID: 25547861. (Published online 30th December 2014. doi: 10.1007/s00702-014-1356-2)
Schwab RS, England AC (1958) Parkinson’s disease. J Chron Dis 8:488–509
Silvestre-Donat FJ, Silvestre-Rangil J (2014) Drooling. Monogr Oral Sci 24:126–134
Srivanitchapoom P, Pandey S, Hallett M (2014) Drooling in Parkinson’s disease: a review. Parkinsonism Relat Disord 20:1109–1118
Zeller M (1999) Speichelsekretion. Provided by Fachschaft Medizin 2000, Julius-Maximilians-Universität Würzburg. Available online under http://zahnmedizinstudenten.de/einzubauen/spei_pro.pdf. Accessed Apr 2015)
Conflict of interest
The author has received speaker’s honoraria and is a consultant for Pharm Allergan, Ipsen Pharma, and Merz Pharmaceuticals. He is the principal investigator of the current clinical trial (MRZ60201_30900_1, clinicaltrials.gov identifier NCT02091739) sponsored by Merz Pharmaceuticals. He reports no conflict of interest with regard to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jost, W.H. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson’s disease. J Neural Transm 123, 51–55 (2016). https://doi.org/10.1007/s00702-015-1416-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-015-1416-2